Dana Investment Advisors Inc. acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 38,474 shares of the biotechnology company’s stock, valued at approximately $701,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in EXEL. Amundi Pioneer Asset Management Inc. increased its stake in shares of Exelixis by 182.1% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 176,193 shares of the biotechnology company’s stock worth $4,193,000 after purchasing an additional 113,733 shares during the period. Total Clarity Wealth Management Inc. bought a new position in Exelixis during the 1st quarter worth $28,000. Seizert Capital Partners LLC bought a new position in Exelixis during the 1st quarter worth $8,888,000. M&T Bank Corp bought a new position in Exelixis during the 1st quarter worth $210,000. Finally, Alliancebernstein L.P. increased its stake in Exelixis by 13.3% during the 1st quarter. Alliancebernstein L.P. now owns 737,812 shares of the biotechnology company’s stock worth $16,667,000 after acquiring an additional 86,400 shares during the period. 83.76% of the stock is owned by institutional investors.
Shares of EXEL opened at $20.13 on Wednesday. The company has a market capitalization of $6.34 billion, a PE ratio of 69.41, a PEG ratio of 0.66 and a beta of 1.07. Exelixis, Inc. has a 12 month low of $16.19 and a 12 month high of $27.35. The stock’s 50-day moving average price is $18.14 and its two-hundred day moving average price is $21.23.
A number of equities analysts have commented on EXEL shares. HC Wainwright restated a “buy” rating and set a $65.00 price objective on shares of Exelixis in a research note on Thursday, September 9th. Oppenheimer reduced their target price on Exelixis from $35.00 to $27.00 and set an “outperform” rating on the stock in a report on Tuesday, June 29th. Needham & Company LLC reduced their target price on Exelixis from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Monday, June 28th. Finally, TheStreet downgraded Exelixis from a “b-” rating to a “c” rating in a report on Friday, July 9th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $34.50.
In related news, EVP Peter Lamb sold 60,000 shares of the business’s stock in a transaction dated Thursday, June 17th. The stock was sold at an average price of $22.18, for a total value of $1,330,800.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 175,000 shares of company stock valued at $3,393,200 over the last ninety days. 3.30% of the stock is currently owned by corporate insiders.
Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.